Association study of myo-inositol monophosphatase 2 (IMPA2) polymorphisms with bipolar affective disorder and response to lithium treatment

Pharmacogenomics Journal

Volumn 5, Issue 1, 2005, Pages 35-41

  Dimitrova, A ^a   Milanova, V ^a   Krastev, S ^a   Nikolov, I ^b   Toncheva, D ^a   Owen, M J ^b   Kirov, G ^b  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Bipolar disorder; IMPA2; Lithium; Response; SNP

Indexed keywords

ESTERASE; LITHIUM; MYOINOSITOL MONOPHOSPHATASE 2; PHOSPHATIDYLINOSITOL; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG RESPONSE; ENZYME INHIBITION; ENZYME POLYMORPHISM; GENE FUNCTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; POLYMORPHIC LOCUS; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ADULT; BIPOLAR DISORDER; HUMANS; LITHIUM; PHOSPHORIC MONOESTER HYDROLASES; POLYMORPHISM, GENETIC;

EID: 13544270229     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500273     Document Type: Article

References (28)

1. McGuffin P, Owen MJ, O'Donovan MC, Thapar A, Gottesman II. Affective disorders (Chapter 6). Seminars in Psychiatric Genetics. Royal College of Psychaitrists: London 1994.
2. Goodwin FK, Jamison KR. Manic-Depressive Illness. Oxford University Press: New York 1990.
3. Manji HK, Potter WZ, Lenox RH. Signal transduction pathways. Arch Gen Psychiatry 1995; 52: 531-543.
4. El-Mallakh RS. Lithium. Actions and Mechanisms. American Psychiatric Press: Washington, DC, London 1996.
5. Lenox RH, Mc Namara RK, Papke, Mangi HK. Neurobiology of lithium: an update. J Clin Psychiatry 1998; 59: 37-47.
6. Berridge MJ, Downes CP, Hanley MR. Neural and developmental action of lithium: a unifying hypothesis. Cell 1989; 59: 411-419.
7. Atack JR. Inositol monophosphatase, the putative therapeutic target for lithium. Brain Res Rev 1996; 22: 183-190.
8. Steen VM, Lovlie R, Osher Y, Belmaker RH, Berle JO, Gulbrandsen AK. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 1998; 8: 259-268.
9. Piccardi MP, Ardau R, Chillotti C, Deleuze JF, Mallet J, Meloni R et al. Manic-depressive illness: an association study with the inositol polyphosphate 1-phosphatase and serotonin transporter genes. Psychiatr Genet 2002; 12: 23-27.
10. Yoshikawa T, Turner G, Esterling LE, Sanders AR, Detera-Wadleigh SD. A novel human myo-inositol monophosphatase gene, IMP.18p maps to a susceptibility region for bipolar disorder. Mol Psychiatry 1997; 2: 393-397.
11. Sjoholt G, Gulbrandsen AK, Lovlie R, Molven A, Steen AM. A human myo-inositol monophosphatase gene (IMPA2) localized in a putative susceptibility region for bipolar disorder on chromosome 18p11.2: genomic structure and polymorphism screening in manic-depressive patients. Mol Psychiatry 2000; 5: 172-180.
12. Yoshikawa T, Padigaru M, Karkera JD, Sharma M, Berrettini WH, Esterling LE et al. Genomic structure and novel variants of myo inositol monophosphatase 2 (IMPA2). Mol Psychiatry 2000; 5 165-171.
13. Sjoholt G, Molven A, Lovlie R, Wilcox A, Sikela JM, Steen VM. Genomic structure and chromosomal location of a human myo-inositol monophosphatase gene (IMPA). Genomics 1997; 45: 113-122.
14. Berrettini WH, Ferraro TN, Goldin LR, Weeks DE, Detera-Wadleigh S, Nurnberger JI et al. Chromosome 18 DNA markers and manic-depressive illness: evidence for a susceptibility gene. Proc Natl Acad Sci USA 1994; 91: 5918-5921.
15. Stine OC, Xu J, Koskela R, McMahon FJ, Gschwend M, Friddle C et al. Evidence for linkage of bipolar disorder to chromosome 18 with a parent-of-origin effect. Am J Hum Genet 1995; 57: 1384-1394.
16. Yoshikawa T, Kikuchi M, Saito K, Watamabe A, Yamada K, Shibuya H et al. Evidence for association of myo-inositol monophosphatase 2 (IMPA2) gene with schizophrenia in Japanese samples. Mol Psychiatry 2000; 6: 202-210.
17. Sjoholt G, Ebstein RP, Lie RT, Berle J, Mallet J, Deleuze JF et al. Examination of IMPA1 and IMPA2 genes in manic-depressive patients: association between IMPA2 promoter polymorphisms and bipolar disorder. Mol Psychiatry 2004; 9: 621-629.
18. The International HapMap Consortium. The International HapMap Project. Nature 2003; 426: 789-796.
19. Georgieva L, Nikolov I, Poriazova N, Jones G, Toncheva D, Kirov G et al. Genetic variation in the seven-pass transmembrane cadherin CELSR1: lack of association with schizophrenia. Psychiatr Genet 2003; 13: 103-106.
20. Wing JK, Babor T, Brugha J, Cooper JE, Giel R, Jablenski A et al. Schedules for clinical assessment in neuropsychiatry. Arch Gen Psychiat 1990; 47: 137-144.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press: Washington, DC 1994.
22. Kirov G, Georgieva L, Williams N, Nikolov I, Norton N, Toncheva D et al. Variation in the protocadherin gamma A gene cluster. Genomics 2003; 82: 433-440.
23. Myakishev MV, Khripin Y, Hu S, Hamer DH. High-throughput SNP genotyping by allele-specific PCR with universal energy-transfer-labeled primers. Genome Res 2001; 11: 163-169.
24. Hawskins JR, Khripin Y, Valdes AM, Weaver TA. Miniaturized sealed-tubes allele-specific PCR. Hum Mutat 2002; 19: 543-553.
25. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993; 52: 506-516.
26. Camp NJ. Genomewide transmission/disequilibrium testing - consideration of the genotypic relative risks at disease loci. Am J Hum Genet 1997; 61: 1424-1430.
27. Lewontin RC. The interaction of selection and linkage. I. General considerations; heterotic models. Genetics 1964; 49: 49-67.
28. Pritchard JK, Przeworski M. Linkage disequilibrium in humans: models and data. Am J Hum Genet 2001; 69: 1-14.